February 28, 2020

Celltrion’s Remsima SC wins European approval

PUBLISHED : November 26, 2019 - 10:24

UPDATED : November 26, 2019 - 10:24

  • 본문폰트 작게
  • 본문폰트 크게
  • 페이스북
  • 트위터
  • sms

South Korean biopharmaceutical firm Celltrion said Nov. 26 that its drug Remsima SC for the treatment of autoimmune diseases has won sales approval in Europe.

The European Medicines Agency has given the green light to Celltrion’s application to sell the subcutaneous version of Remsima, a biosimilar copy of Janssen Biotech’s Remicade, according to the company. 

Remsima, administered through intravascular injections, is used in the treatment of a number of diseases, from rheumatoid arthritis to Crohn’s disease, Celltrion said. The SC version allows patients to conveniently inject it by themselves, unlike the intravenous formulation that requires patients to visit hospitals.

The authorization comes nearly a year after Celltrion sent the application to the EMA.

“The product is the first SC version of the treatment, offering a unique selling point in the global TNF-alpha inhibitor (autoimmune disease therapeutic agent) market” said a company official who asked not to be named.

The development of the SC formulation of Remsima is one of Celltrion’s marketing strategies to increase its share of the global TNF-alpha inhibitor market, estimated to be worth 50 trillion won ($42.6 billion).

By Ram Garikipati and newswires (

  • 페이스북
  • 트위터
  • sms
Herald Corporation|CEO : Kwon Chung Won
Publisher. Editor : Kwon Chung Won
Chief Privacy Officer & Juvenile Protection Manager : Yang Sung-jin
Title : The Investor|Date of registration : 2015.04.28
Company Registration No. 104-81-06004
Mail-Order Business Registration 2016 - Seoul Yongsan - 00590
Huam-ro 4-gil 10, Yongsan-gu, Seoul, Korea
T : +82-2-727-0114|Business info
Gov’t registration No. Seoul 아04099